Introduction
============

Oral squamous cell carcinoma (OSCC) is the most common type of head and neck squamous cell carcinoma (HNSCC), and is among the 10 most prevalent cancer types worldwide ([@b1-ol-0-0-7108],[@b2-ol-0-0-7108]). In spite of improvements in the diagnosis and prognosis of OSCC, long-term survival rates have not improved in the past decade ([@b3-ol-0-0-7108]). To develop effective therapies, an improved understanding of the biological features and underlying molecular mechanisms of OSCC are required.

In previous studies, it has been suggested that the cancer stem cell (CSC) hypothesis may be applied to a number of types of cancer ([@b4-ol-0-0-7108],[@b5-ol-0-0-7108]). According to the hypothesis, a tumor may be viewed as an aberrant organ initiated by a subpopulation of cells, termed CSCs, which exhibit self-renewing capacities and are responsible for tumor maintenance and metastasis ([@b6-ol-0-0-7108]). The hypothesis provides a novel insight into the understanding of tumorigenesis and since then, the isolation and identification of CSCs have been studied in depth. Previous studies have supported the validity of this hypothesis in a number of malignant diseases, including breast cancer, brain tumor, colon cancer, melanomas and prostate cancer ([@b7-ol-0-0-7108]--[@b11-ol-0-0-7108]). In addition, the existence of CSCs has been identified in HNSCC and has been associated with the expression of aldehyde dehydrogenase (ALDH) ([@b12-ol-0-0-7108]). Cells with increased ADLH 'bright' activity (ALDH^br^) exhibit CSC-associated properties, including radio-resistance and the ability to produce tumors with a limited number of cells, which is in contrast to cells with decreased ALDH activity (ALDH^low^) ([@b13-ol-0-0-7108],[@b14-ol-0-0-7108]). However, the gene expression profile of the two cell subpopulations remains unknown, which is required to understand the underlying molecular mechanisms of CSCs in HNSCC.

In the present study, ALDH^br^ and ALDH^low^ cells were isolated from the OSCC TCA8113 cell line and suppression subtractive hybridization (SSH) was subsequently performed to identify differentially expressed genes in the two subpopulations. Known and unknown differentially expressed genes were identified in subtracted clones, and the known genes were functionally characterized using bioinformatical tools. The results of the present study suggested that the identified genes may be biomarkers for the identification of CSCs in OSCC.

Materials and methods
=====================

### Cells and cell culture

The tongue squamous cell carcinoma TCA8113 cell line was obtained from the West China College of Stomatology of Sichuan University (Sichuan, China). Cells were maintained in RPMI 1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 1% glutamine and 1% penicillin-streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~.

### ALDH assay and cell sorting

An Aldefluor kit (Stemcell Technologies, Inc., Vancouver, BC, Canada) was used to determine ALDH activity in TCA8113 cells, according to the manufacturer\'s protocol. Cells were suspended in Aldefluor assay buffer, which contained an activated Aldefluor substrate (BAAA, 1 µmol/1×10^6^ cells), as recommended by the manufacturer. As a negative control for all samples, an aliquot of 'Aldefluor-exposed' cells (1×10^8^ cells) was transfused into the control tube, which contained 5 µl diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. Following incubation at 37°C for 40 min, the cells were centrifuged at 250 × g for 5 min and the supernatant was removed. Subsequently, the cell pellets were resuspended in 0.5 ml ice-cold Aldefluor Assay Buffer, and flow cytometric analysis was performed using FACSAria (BD Biosciences, Franklin Lakes, NJ, USA). Aldefluor staining was determined using a green fluorescence channel. Samples treated with DEAB were used as controls and set the threshold that defined the ALDH^br^ region.

### Tumorsphere formation

Since CSCs typically form tumorspheres and non-CSCs die in serum-free medium ([@b15-ol-0-0-7108],[@b16-ol-0-0-7108]), tumorsphere formation in ALDH^br^ and ALDH^low^ cells was investigated in the present study. Cells were plated at a low density (1,000 cells/ml) in RPMI1 640 serum-free medium, supplemented with human recombinant epidermal growth factor (20 ng/ml; PeproTech, Inc., Rocky Hill, NJ, USA), basic fibroblast growth factor (20 ng/ml; PeproTech, Inc.) and B27 serum-free supplements (20 µl/ml; Invitrogen; Thermo Fisher Scientific, Inc.). The formation of tumorspheres was observed daily using an inverted phase contrast microscope (magnification, ×100).

### Preparation of total RNA

Total RNA was isolated from ALDH^br^ and ALDH^low^ cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Total RNA was quantified using a Unico UV-2000 spectrophotometer (Unico Technologies Co., Ltd., Jiangsu, China). The A~260~/A~280~ ratio was between 1.8 and 2.0. Total RNA (\~1 µg) was separated on denaturing agarose (1.2% gel) to confirm integrity.

### cDNA synthesis

cDNA was synthesized using the SMART™ cDNA Synthesis kit (Clontech Laboratories, Inc., Mountain View, CA, USA) according to the manufacturer\'s protocol. Total RNA (1 µg) was reverse transcribed (42°C, 1.5 h) in a 10-µl reaction mixture containing PowerScript™ reverse-transcriptase. Sterile H~2~O (24.2 µl), 5X Second-Strand Buffer (8.0 µl), dNTP mix (10 mM; 0.8 µl) and 20X Second-Strand Enzyme Cocktail (2.0 µl) were added to the 10 µl first-strand synthesis reaction tubes and incubated at 16°C for 2 h in water. T4 DNA polymerase (Clontech Laboratories, Inc.) 2 µl was then added followed by incubation at 16°C for 30 min in a water bath. Subsequently, 4 µl of 20X EDTA/glycogen mix was added to terminate second-strand synthesis, followed by addition of 100 µl of phenol:chloroform:isoamyl alcohol (25:24:1). Centrifugation was then performed at 2,191.28 × g for 10 min at room temperature. The top aqueous layer was collected and placed in a fresh 0.5-ml microcentrifuge tube. The inter and lower phases were discarded and disposed appropriately. Next, 100 µl of chloroform:isoamyl alcohol (24:1) was added, followed by addition of 40 µl of 4 M NH~4~OAc and 300 µl of 95% ethanol. Subsequently, centrifugation was performed at 2,191.28 × g for 20 min at room temperature, and the supernatant was collected. The pellet was overlayed with 500 µl of 80% ethanol, and then centrifuged at 2,191.28 × g for 10 min at room temperature. The supernatant was removed and the pellet was air-dried for \~10 min to evaporate residual ethanol. Precipitate was dissolved in 50 µl of sterile H~2~O, and 6 µl was transferred to a fresh microcentrifuge tube. This sample was stored at −20°C until after *Rsa*I digestion (for agarose gel electrophoresis) to estimate yield and size range of ds cDNA products synthesized.

### SSH

Synthesized two-target cDNA was used for SSH, performed with the PCR-select™ cDNA Subtraction kit (Clontech Laboratories, Inc.), according to the manufacturer\'s protocol. cDNA from ALDH^br^ and ALDH^low^ cells was used as the 'tester' and 'driver', respectively, in the forward subtraction and vice versa for the reverse subtraction. For each subtraction, the 'tester' was ligated to adaptor 1 and adaptor 2R in separate ligation reactions, whereas the 'driver' was not ligated to adaptors. Following ligation, two samples were subjected to hybridization. For the first hybridization, an excess of 'driver' cDNA was added to each adaptor-ligated 'tester' cDNA in the hybridization buffer, heat-denatured (98°C, 1.5 min) and subsequently annealed (68°C, 8 h). The two samples from the first hybridization were mixed and fresh denatured 'driver' cDNA was added and annealed at 68°C overnight. Following the second hybridization, the sample was diluted in 200 µl dilution buffer and incubated at 68°C for 7 min in a thermal cycler. Subsequently, PCR was performed using the subtracted cDNAs to amplify the desired differentially expressed sequences. The first-round PCR was performed using PCR primer 1 (5′-CTAATACGACTCACTATAGGGC-3′) and the cycling parameters were 72°C for 10 min and 95°C for 2 min, followed by 25 cycles of 94°C for 30 sec, 62°C for 45 sec, 72°C for 1 min and 72°C for 6 min. The second-round PCR reaction was performed using nested primer 1 (5′-TCGAGCGGCCGCCCGGGCAGGT-3′) and nested primer 2R (5′-AGCGTGGTCGCGGCCGAGGT-3′), and the cycling parameters were 95°C for 2 min, followed by 29 cycles of 94°C for 30 sec, 65°C for 45 sec, 72°C for 1 min and 72°C for 6 min.

### Cloning of SSH-PCR products

The purified secondary SSH-PCR products were cloned into PMD-18T vector (Takara Bio, Inc., Otsu, Japan) and the ligated products were transformed into *E. coli* DH5α competent cells. Transformed colonies were selected on Luria-Bertani (LB) agar medium (MP Biomedicals, Santa Ana, CA, USA) containing ampicillin (100 mg/l) at 37°C and \~1,000 positive colonies were obtained, which represented subtraction libraries enriched with differentially expressed genes. A total of 240 positive colonies were selected randomly. A single clone was inoculated in 2 ml LB-ampicillin (100 mg/l) and incubated overnight at 37°C with gentle agitation at 44.72 × g.

### PCR amplification of cDNA inserts

To assess the size of inserts, colony PCR was performed in a 50-µl reaction system containing 12.5 µl 10X buffer (Takara Bio, Inc.), 1 µl 10 mM dNTP (Shanghai CPG Biotechnology Co., Ltd., Shanghai, China), 5 µl MgCl~2~ (Takara Bio, Inc.), 1 µl 50 pM/µl Nested primer 1 (Clontech Laboratories, Inc.), 1 µl 50 pM/µl 2R primer (Clontech Laboratories, Inc.), and 2.5 U Taq DNA polymerase (Takara Bio, Inc.). The PCR parameters were: 95°C for 2 min, followed by 35 cycles of 95°C for 30 sec, 62°C for 45 sec and 72°C for 1 min. Colony PCR products (2 µl) were separated using agarose (1.2% gel) to identify the presence and the size of the inserts prior to sequencing. The controls for this protocol included the unsubtracted tester control for the forward subtraction, the unsubtracted tester control for the reverse subtraction and the unsubtracted tester control for the control skeletal muscle tester cDNA \[made from the Control Poly A^+^ RNA (from human skeletal muscle) provided with the kit (the SMART™ cDNA Synthesis kit (Clontech Laboratories, Inc.)\]. It serves as control driver cDNA subtraction. All protocols were repeated 3 times.

### Expressed sequenced tag (EST) sequencing and bioinformatical analysis

The selected positive clones were sequenced at the Beijing Genomics Institute (Beijing, China) and the sequences were edited to remove the adaptor-primer and vector DNA sequences. ESTs were compared with non-redundant public databases using the Basic Local Alignment Search Tool (BLAST) ([blast.ncbi.nlm.nih.gov/Blast.cgi](blast.ncbi.nlm.nih.gov/Blast.cgi)) nucleotide to retrieve data from GenBank ([www.ncbi.nlm.nih.gov/nucleotide](www.ncbi.nlm.nih.gov/nucleotide)) and BLASTX ([blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastx&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome](blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastx&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome)) algorithms of the National Center for Biotechnology Information (NCBI; [blast.ncbi.nlm.nih.gov/Blast.cgi](blast.ncbi.nlm.nih.gov/Blast.cgi)). ESTs with E\<0.01 were deemed to exhibit significant homology. Homologies \>50 nucleotides that exhibited \>90% identity to sequences in the database were considered to have significant homologies, as previously described ([@b17-ol-0-0-7108]). The physiological functions of these ESTs were classified according to Gene Ontology ([www.geneontology.org](www.geneontology.org)). Pathway analysis was performed using the Gene Set Analysis Toolkit V2 online system ([www.webgestalt.org/option.php](www.webgestalt.org/option.php)).

Results
=======

### Isolation of ALDH^br^ cells in tongue squamous cell carcinoma TCA8113 cells

Using the ALDEFLUOR assay and fluorescence-activated cell sorting analysis, the ALDH enzymatic activity in the tongue squamous cell carcinoma TCA8113 cell line was identified to be heterogeneous. As presented in [Fig. 1](#f1-ol-0-0-7108){ref-type="fig"}, only a limited proportion (1.3%) of the cells displayed increased ALDH activity (ALDH^br^; [Fig. 1A](#f1-ol-0-0-7108){ref-type="fig"}), whereas the remaining cells expressed decreased levels of ALDH activity (ALDH^low^). DEAB, the specific inhibitor of ALDH, resulted in a decreased proportion of sorted ALDH^br^ cells (0.1%; [Fig. 1B](#f1-ol-0-0-7108){ref-type="fig"}), suggesting the effective isolation of ALDH^br^ cells. The results of the present study revealed that cancer stem cells with ALDH^br^ were successfully isolated. Subpopulation cells were selected for additional analysis.

### ALDH^br^ cells form spheres

CSCs may be effectively enriched in serum-free medium ([@b18-ol-0-0-7108]--[@b20-ol-0-0-7108]). The majority of cells die in serum-free medium due to a lack of nutritive materials; however, CSCs may survive, proliferate and form three-dimensional spheres. In the present study, ALDH^br^ cells maintained in serum-free medium proliferated and formed spheres within 5 days, whereas ALDH^low^ cells, maintained in the same medium, did not form spheres and were apoptotic ([Fig. 2](#f2-ol-0-0-7108){ref-type="fig"}). The results of the present study indicated that the isolated ALDH^br^ cells exhibited typical CSC features.

### Constructing the SSH library

Using cDNA from ALDH^br^ cells as 'testers' and that of ALDH^low^ cells as 'drivers' and vice versa, PCR-selected cDNA subtraction for forward and reverse libraries, respectively, was performed. Following subtraction, a pool of putative differentially expressed cDNA fragments was obtained. The cDNA fragments ranged between 200 bp and 1 kb, with the majority distributed between 400 and 600 bp ([Fig. 3A](#f3-ol-0-0-7108){ref-type="fig"}). Subtracted amplicons were ligated into the PMD-18T plasmid vector and transformed into *E. coli* DH5α competent cells. In total, 240 white colonies were randomly selected and 48 of these clones were subjected to colony PCR, using nested primers. All the recombinants determined revealed amplicons ranging between 200 and 800 bp ([Fig. 3B](#f3-ol-0-0-7108){ref-type="fig"}).

### Identification of differentially expressed ESTs

All 240 clones were selected and sequenced. Sequences were not obtained for 14 clones and those were omitted from the present study. Comparison of the unique sequences obtained from each library against the GenBank databases identified 104 unique clones, 62 of which corresponded to known genes and 42 of which were unknown genes, while the remaining 122 clones were redundant. Of the known genes, 28 and 34 genes were upregulated and downregulated in ALDH^br^ cells, respectively ([Tables I](#tI-ol-0-0-7108){ref-type="table"} and [II](#tII-ol-0-0-7108){ref-type="table"}). The unknown clones were divided into two groups in the NCBI databases, 28 represented human genomic sequences and 14 were present in the human EST database.

### Functional classification of differentially expressed ESTs

On the basis of the functional annotation using Gene Ontology (GO) software, 62 differentially expressed genes were grouped into a number of categories ([Fig. 4](#f4-ol-0-0-7108){ref-type="fig"}). In the GO category of biological processes, the highly enriched categories included those associated with metabolic processes (28 genes), biological regulation (21 genes) and developmental processes (16 genes). The molecular functions with those highly enriched genes were associated with protein binding (32 genes) and cellular components in the nucleus (24 genes).

### Pathway analysis of differentially expressed ESTs

Signal pathway analysis was performed based on the Wikipathways database and the Pathway Commons database, using the Gene Set Analysis Toolkit V2. The 10 signaling pathways with the most marked alterations in each database are presented in [Tables III](#tIII-ol-0-0-7108){ref-type="table"} and [IV](#tIV-ol-0-0-7108){ref-type="table"}, and included the transforming growth factor (TGF-) β signaling pathway, the Notch signaling pathway and the c-kit pathway. Typically, \~10 genes were enriched in these pathways and each gene may participate in a number of pathways.

Discussion
==========

CSCs refer to a subset of tumor cells that exhibit the capability to self-renew and generate diverse cells that comprise the tumor ([@b4-ol-0-0-7108],[@b21-ol-0-0-7108]), and have been termed CSCs to reflect the 'stem-like' properties and the ability to sustain tumorigenesis. CSCs share important properties with healthy tissue stem cells, including the capacity for self-renewal and differentiation. An implication of the CSC hypothesis is that cancer cells are hierarchically arranged with CSCs located at the apex of the hierarchy ([@b22-ol-0-0-7108]). CSCs are the only cells that may maintain tumor viability indefinitely. The remaining cells, although actively proliferating and comprising the majority of the tumor, are differentiating and destined to die. The identification of CSCs has marked implications in the study of cancer biology. Previous studies ([@b7-ol-0-0-7108]--[@b11-ol-0-0-7108]) have indicated the existence of CSCs in a number of solid tumors and a variety of cell surface makers have been used to isolate CSC subpopulations, including cluster of differentiation (CD)24, CD133 and CD24; however, none of these markers are exclusively expressed by CSCs in solid tumors.

ALDH is a member of the family of NAD(P)^+^-dependent enzymes involved in detoxifying a variety of aldehydes to the corresponding weak carboxylic acids ([@b23-ol-0-0-7108]). The use of ALDH activity in flow cytometry-based methods has enabled the isolation of viable CSC subpopulations in a number of cancer types ([@b24-ol-0-0-7108]--[@b26-ol-0-0-7108]). In the present study, CSCs were enriched from the tongue squamous cell carcinoma TCA8113 cell line, according to the overexpression of ALDH^br^. ALDH^br^ cells comprised 1.3% of the total cell population, which is consistent with previous studies ([@b13-ol-0-0-7108],[@b14-ol-0-0-7108]). Therefore, ALDH^br^-associated CSCs were successfully isolated for additional investigation.

In order to identify stem cell associated genes differentially expressed in ALDH^br^ and ALDH^low^ cells, SSH was performed. SSH is advantageous compared with other PCR-based techniques as it selectively amplifies target cDNA fragments (differentially expressed), and simultaneously suppresses non-target DNA amplification, to generate a library of differentially expressed sequences ([@b27-ol-0-0-7108]). The normalization step equalizes the abundance of cDNAs within a target population and the subtraction step excludes the common sequences between the driver and tester populations ([@b27-ol-0-0-7108]). In addition, the advantage compared with microarrays is that SSH may isolate novel differentially expressed genes ([@b28-ol-0-0-7108]). In the present study, two SSH libraries were constructed from cDNAs obtained from ALDH^br^ and ALDH^low^ cells, and a total of 240 clones were selected and sequenced. Using GenBank databases, 28 and 34 known genes were identified from the forward and reverse libraries, respectively. A total of 28 of clones revealed homology with chromosome sequences and 14 clones demonstrated homology with ESTs. The known genes were grouped into functional categories on the basis of GO.

In the GO category of biological process, the highly enriched categories included those associated with metabolic processes (28 genes), biological regulation (21 genes) and developmental processes (16 genes). The results of the present study suggested that abnormal stem cell homeostasis associated with the aforementioned processes would result in malignant changes in stem cells.

Signaling pathway analysis identified the 10 pathways that exhibited marked alterations in the Wikipathways database and Pathway Commons database, which included Notch and TGF-β signaling pathways, which have been identified to serve important roles in the regulation of stem cell self-renewal, multi-potency and cell-fate determination ([@b29-ol-0-0-7108],[@b30-ol-0-0-7108]). In addition, one gene may participate in different signaling pathways at the same time; for example, the gene encoding cAMP response element-binding protein (CREB) binding protein (CREBBP/CBP) was involved in 7 of the aforementioned signaling pathways and notably interacted with Wnt signaling to maintain the pluriporency of murine embryonic stem cells in long-term culture ([@b31-ol-0-0-7108]). A previous study demonstrated that CBP was critical in maintaining an adequate pool of murine hematopoietic stem cells through self-renewal and was important for preventing hematological tumor formation ([@b32-ol-0-0-7108]), suggesting that CBP was associated with the biological regulation of normal stem cells. There have been a limited number of studies on the expression and function of CBP in CSCs, therefore, whether CBP is a marker of CSCs in tongue squamous cell carcinoma remains unknown. Additionally, nuclear receptor corepressor 1 (NCOR1) was involved in a number of signaling pathways and was initially defined as a regulator of nuclear receptor-mediated repression. NCOR is expressed in the nucleus of neural stem cells (NSCs) and is a regulator of neural stem cells. Following phosphorylation, NCOR translocates to the cytoplasm and induces the astrocytic differentiation of NSCs ([@b33-ol-0-0-7108]). Furthermore, NCOR has been identified to maintain normal intestinal epithelial cell viability, and silencing of NCOR1 expression in proliferating cells of crypt origin resulted in a rapid viability arrest without associated cell death ([@b34-ol-0-0-7108]). In glioblastoma multiforme (GBM), NCOR was expressed in the nucleus of undifferentiated CSCs and the nuclear localization of NCOR may function as a marker of GBM stem cells ([@b35-ol-0-0-7108]).

Differentially expressed genes in tongue squamous carcinoma stem-like cells were profiled using the SSH technique. A total of 62 genes were identified as upregulated or downregulated in tongue squamous carcinoma stem-like cells (termed ALDH^br^ cells), suggesting that distinct gene expression profiles are present in CSCs. CBP and NCOR1 genes were involved in a number of signaling pathways in ALDH^br^ cells. The results of a literature review suggested that CBP and NcoR1 may be CSCs markers ([@b32-ol-0-0-7108]--[@b35-ol-0-0-7108]), which is consistent with the results of the present study. Although the results of the present study are preliminary, a group of candidate genes have been identified, which require additional study.
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![Isolation of ALDH^br^ cells in tongue squamous cell carcinoma TCA8113 cells. (A) Cells incubated with Aldefluor substrate (BAAA) and subsequent fluorescence-activated cell sorting was used to identify cells exhibiting increased ALDH activity (P2 region, 1.3%). (B) With the addition of DEAB, a specific inhibitor of ALDH, the proportion of sorted ALDH^br^ cells was markedly decreased (P2 region, 0.1%). ALDH, aldehyde dehydrogenase; DEAB, diethylaminobenzaldehyde; SSC-A, side scatter area.](ol-14-06-7055-g00){#f1-ol-0-0-7108}

![Sphere formation of cells exhibiting increased ALDH activity. Isolated cells exhibiting increased and decreased ALDH activity were maintained in serum-free RPMI 1640 medium. Cells were subsequently inspected using an inverted phase contrast microscope (magnification, ×100) at a variety of culture times. Cells exhibiting increased ALDH activity formed spheres on (A) day 5 and (B) day 10; (C) whereas cells exhibiting decreased activity of ALDH died on day 5. ALDH, aldehyde dehydrogenase.](ol-14-06-7055-g01){#f2-ol-0-0-7108}

![Construction of the suppression substrate hybridization library. (A) Products of PCR-select cDNA subtraction. (B) cDNA fragments of distinct lengths from white clones, amplified using PCR. PCR, polymerase chain reaction; M, DNA marker; 1, forward subtraction products; 2, reverse subtraction products.](ol-14-06-7055-g02){#f3-ol-0-0-7108}

![Functional classification of differentially expressed ESTs. (A) Biological process of differentially expressed ESTs. (B) Molecular function of differentially expressed ESTs. (C) Cell component of differentially expressed ESTs. EST, expressed sequence tag.](ol-14-06-7055-g03){#f4-ol-0-0-7108}

###### 

Characteristics of overexpressed known genes in aldehyde dehydrogenase-positive subpopulation cells.

  No.   Length, bp   Gene                                                                                                   Accession no.              Identities (%)   E-value          Gene ID                  Gene symbol    Chromosomal location
  ----- ------------ ------------------------------------------------------------------------------------------------------ -------------------------- ---------------- ---------------- ------------------------ -------------- ----------------------
  1     206          *Drosophila* melanogaster CG4699 (CG4699), transcript variant J                                        ref\|NM_001170153.1\|      163/166 (99)     2.00×10^−76^     41911 CG4699             CG4699 (WAH)   Unknown
  2     402          *Homo sapiens* solute carrier family 25, member 13 (citrin) (SLC25A13), RefSeqGene on chromosome 7     ref\|NG_012247.1\|         388/389 (99)     0                10165                    SLC25A13       7q21.3
  3     303          *Homo sapiens* kelch-like 2, Mayven (*Drosophila*) (KLHL2), transcript variant 3, mRNA                 ref\|NM_001161522.1\|      284/285 (99)     8.00×10^−145^    11275 KLHL2              KLHL2          4q21.2
  4     225          *Homo sapiens* Niemann-Pick disease, type C1 (NPC1), RefSeqGene on chromosome 18                       ref\|NG_012795.1\|         174/175 (99)     3.00×10^−83^     4864                     NPC1             18q11-q12
  5     369          *Homo sapiens* EP300 interacting inhibitor of differentiation 1 (EID1), mRNA                           ref\|NM_014335.2\|         353/354 (99)     0                23741 EID1               EID1           15q21.1-q21.2
  6     289          *Homo sapiens* notch 2 (NOTCH2), RefSeqGene on chromosome 1                                            ref\|NG_008163.1\|         512/514 (99)     0                4853                     NOTCH2         1p13-p11
  7     234          *Homo sapiens* BRCA1 associated RING domain 1 (BARD1), RefSeqGene                                      ref\|NG_012047.1\|         215/216 (99)     1.00×10^−106^    157266327                BARD1          2q34-q35
  8     272          *Homo sapiens* inositol 1,4,5-triphosphatereceptor, type 1 (ITPR1), RefSeqGene on chromosome 3         ref\|NG_016144.1\|         253/254 (99)     1.00Ex10^−127^   269954693                ITPR1          3p26-p25
  9     289          *Homo sapiens* FRG1 (FRG1) gene, complete cds;                                                         gb\|AF146191.1\|AF146191   264/272 (98)     2.00×10^−125^    AAD46768.1               FRG1           4q35
  10    280          *Homo sapiens* methylcrotonoyl-CoA carboxylase 2 (beta) (MCCC2), RefSeqGene on chromosome 5            ref\|NG_008882.1\|         263/263 (100)    3.00×10^−134^    64087                    MCCC2          5q12-q13
  11    410          *Homo sapiens* ribosomal protein, large, P0 (RPLP0), transcript variant 1, mRNA                        ref\|NM_001002.3\|         388/390 (99)     0                6175 RPLP0               RPLP0          12q24.2
  12    468          *Homo sapiens* dedicator of cytokinesis 8 (DOCK8), transcript variant 3, mRNA                          ref\|NM_001193536.1\|      449/450 (99)     0                81704 DOCK8              DOCK8          9p24.3
  13    365          *Homo sapiens* GLIS family zinc finger 3 (GLIS3), RefSeqGene on chromosome 9                           ref\|NG_011782.1\|         342/347 (99)     1.00×10^−172^    169792                   GLIS3          9p24.2
  14    412          *Homo sapiens* PARK2 co-regulated (PACRG) on chromosome 6                                              ref\|NG_011525.1\|         352/392 (90)     5.00×10^−138^    135138                   PACRG          6q26
  15    153          *Homo sapiens* collagen, type VII, alpha 1(COL7A1), mRNA                                               ref\|NM_000094.3\|         134/135 (99)     7.00×10^−63^     1294 COL7A1              COL7A1         3p21.1
  16    226          *Homo sapiens* epidermal growth factor receptor(EGFR), RefSeqGene on chromosome 7                      ref\|NG_007726.1\|         207/208 (99)     3.00×10^−102^    1956                     EGFR           7p12
  17    450          *Homo sapiens* neuron navigator 2 (NAV2), transcript variant 4, mRNA                                   ref\|NM_001111019.1\|      391/399 (98)     0                89797 NAV2               NAV2           11p15.1
  18    288          *Homo sapiens* retinoblastoma 1 (RB1), mRNA                                                            ref\|NM_000321.2\|         269/270 (99)     1.00×10^−137^    5925 RB1                 RB1            13q14.2
  19    274          *Homo sapiens* tetratricopeptide repeat protein 12 (TTC12) gene, complete cds, alternatively spliced   gb\|EF445041.1\|           214/257 (84)     4.00×10^−58^     ACA06092.1               TTC12          11q23.1
  20    232          *Homo sapiens* nuclear receptor corepressor 1 (NCOR1), transcript variant 3, mRNA                      ref\|NM_001190440.1\|      213/214 (99)     1.00×10^−106^      9611 NCOR1             NCOR1          17p11.2
  21    283          *Homo sapiens* SMAD family member 1 (SMAD1), transcript variant 2, mRNA                                ref\|NM_001003688.1\|      262/263 (99)     1.00×10^−133^    4086 SMAD1               SMAD1          7p15
  22    646          *Homo sapiens* kelch-like 13 (*Drosophila*) (KLHL13), RefSeqGene on chromosome X                       ref\|NG_016759.1\|         628/630 (99)     0                90293                    KLHL13         Xq23-q24
  23    418          *Homo sapiens* PRP39 pre-mRNA processing factor 39 homolog (*S. cerevisiae*) (PRPF39), mRNA            ref\|NM_017922.3\|         395/399 (99)     0                55015 PRPF39             PRPF39         14q21.3
  24    398          *Homo sapiens* septin 9 (SEPT9), transcript variant 4, mRNA                                            ref\|NM_001113495.1\|      379/380 (99)     0                10801 SEPT9              SEPT           17q25
  25    537          *Homo sapiens* ATPase, Ca^++^ transporting, plasma membrane 4 (ATP2B4), transcript variant 1, mRNA     ref\|NM_001001396.1\|      186/188 (99)     5.00×10^−90^     493 ATP2B4               ATP2B4         1q32.1
  26    392          PREDICTED: *Homo sapiens* hypothetical LOC441072 (FLJ31104), partial miscRNA                           ref\|XR_113742.1\|         203/225 (91)     3.00×10^−76^     441072 FLJ31104          FLJ31104       5q11.2
  27    227          *Homo sapiens* CD44 molecule (Indian blood group) (CD44), RefSeqGene on chromosome 11                  ref\|NG_008937.1\|         207/207 (100)    3.00×10^−103^    960                      CD44           11p13
  28    364          Pongo abelii probable methyltransferase TARBP1-like (LOC100447859), mRNA                               ref\|XM_002809289.1\|      120/124 (97)     3.00×10^−51^     100447859 LOC100447859   LOC100447859   Unknown

###### 

Characteristics of downregulated known genes in aldehyde dehydrogenase-positive subpopulation cells.

  No.   Length, bp   Gene                                                                                                                            Accession no.           Identities (%)    E-value         Gene ID                  Gene symbol    Chromosomal location
  ----- ------------ ------------------------------------------------------------------------------------------------------------------------------- ----------------------- ----------------- --------------- ------------------------ -------------- ----------------------
  1     410          Pan troglodytes hypothetical protein LOC736141 (LOC736141), mRNA                                                                ref\|XM_001135501.1\|   322/364 (89)      3.00×10^−117^     736141 LOC736141       LOC736141      X
  2     505          *Homo sapiens* claudin domain containing 1 (CLDND1), transcript variant 6, mRNA                                                 ref\|NM_001040199.1\|   318/320 (99)      9.00×10^−163^   56650 CLDND1             CLDND1         3q12.1
  3     383          *Homo sapiens* ankyrin repeat domain 36B (ANKRD36B), mRNA                                                                       ref\|NM_025190.3\|      297/368 (81)      4.00×10^−70^    57730 ANKRD36B           ANKRD36B       2q11.2
  4     357          *Homo sapiens* catenin (cadherin-associated protein), alpha 1, 102 kDa (CTNNA1), mRNA                                           ref\|NM_001903.2\|      336/337 (99)      1.00×10^−174^   1495 CTNNA1 \|           CTNNA1         5q31
  5     364          *Homo sapiens* electron-transfer-flavoprotein, alpha polypeptide (ETFA), RefSeqGene on chromosome 15                            ref\|NG_007077.2\|        344/346 (99)    5.00×10^−177^   2108                     ETFA           15q23-q25
  6     493          Pan troglodytes RAB7, member RAS oncogene family-like 1, transcript variant 1 (RAB7L1), mRNA                                    ref\|XM_001162387.1\|   264/296 (90)      9.00×10^−98^    469654 RAB7L1            RAB7L1         1q32
  7     635          *Homo sapiens* wings apart-like homolog (*Drosophila*) (WAPAL), mRNA                                                            ref\|NM_015045.2\|      617/618 (99)      0               23063 WAPAL              WAPAL/WAPL     10q23.2
  8     459          *Homo sapiens* KIAA0101 (KIAA0101), transcript variant 2, mRNA                                                                  ref\|NM_001029989.1\|   441/442 (99)      0               9768 KIAA0101            KIAA0101/PAF   15q22.31
  9     299          *Homo sapiens* RAN binding protein 10 (RANBP10), mRNA                                                                           ref\|NM_020850.1\|        281/281 (100)   2.00×10^−145^   57610 RANBP10            RANBP10        16q22.1
  10    224          *Homo sapiens* mitochondrial ribosomal protein S27 (MRPS27), nuclear gene encoding mitochondrial protein, mRNA                  ref\|NM_015084.2\|      202/204 (99)      2.00×10^−99^    23107 MRPS27             MRPS27         5q13.2
  11    426          *Homo sapiens* vacuolar protein sorting 13 homolog A (*S. cerevisiae*) (VPS13A), RefSeqGene on chromosome 9                     ref\|NG_008931.1\|      408/410 (99)      0               23230                    VPS13A         9q21
  12    413          *Homo sapiens* SET binding factor 2 (SBF2), RefSeqGene on chromosome 11                                                         ref\|NG_008074.1\|      392/396 (99)      0               81846                    SBF2           11p15.4
  13    613          *Homo sapiens* MT-RNR2-like 2 (MTRNR2L2), mRNA                                                                                  ref\|NM_001190470.1\|   562/597 (95)      0               100462981                MTRNR2L2       Unknown
  14    423          *Homo sapiens* MT-RNR2-like 8 (MTRNR2L8), mRNA                                                                                  ref\|NM_001190702.1\|   373/399 (94)      9.00×10^−167^     100463486 MTRNR2L8     MTRNR2L8       Unknown
  15    588          *Homo sapiens* WD repeat domain 7 (WDR7), transcript variant 2, mRNA                                                            ref\|NM_052834.2\|      133/133 (100)     2.00×10^−63^    23335 WDR7               WDR7           18q21.1-q22
  16    261          Pan troglodytes similar to ORF1; putative (LOC745921), mRNA                                                                     ref\|XR_021946.1\|      276/326 (85)      6.00×10^−83^    745921 LOC745921         LOC745921      Unknown
  17    459          *Homo sapiens* ornithine decarboxylase 1 (ODC1), mRNA                                                                           ref\|NM_002539.1\|      570/570 (100)     0               4953 ODC1 \|             ODC1           2p25
  18    411          *Homo sapiens* ataxin 7 (ATXN7), RefSeqGene on chromosome 3                                                                     ref\|NG_008227.1\|      393/394 (99)      0               80145                    ATXN7          3p21.1-p12
  19    494          *Homo sapiens* zinc finger protein 573 (ZNF573), transcript variant 5, mRNA                                                     ref\|NM_001172692.1\|   476/476 (100)     0               126231 ZNF573            ZNF573         19q13.12
  20    538          *Homo sapiens* bromodomain containing 2 (BRD2), transcript variant 3, mRNA                                                      ref\|NM_001199455.1\|   297/299 (99)      4.00×10^−151^   6046 BRD2                BRD2           6p21.3
  21    353          PREDICTED: Pan troglodytes similar to uracil DNA glycosylase (LOC743143), mRNA                                                  ref\|XR_021793.1\|      326/332 (98)      2.00×10^−163^   743143 LOC743143         LOC743143      Unknown
  22    380          *Homo sapiens* SET nuclear oncogene (SET), transcript variant 1, mRNA                                                           ref\|NM_001122821.1\|   360/360 (100)     0               6418 SET                 SET            9q34
  23    205          *Homo sapiens* peroxisomal biogenesis factor 19 (PEX19), transcript variant 4, mRNA                                             ref\|NM_001193644.1\|   184/185 (99)      2.00×10^−90^    5824 PEX19               PEX19          1q22
  24    386          *Homo sapiens* microphthalmia-associated transcription factor (MITF), RefSeqGene on chromosome 3                                ref\|NG_011631.1\|      369/369 (100)     0               4286                     MITF           3p14.2-p14.1
  25    449          *Homo sapiens* fatty acid desaturase 1 (FADS1), mRNA                                                                            ref\|NM_013402.4\|      431/432 (99)      0               3992 FADS1               FADS1          11q12.2-q13.1
  26    352          *Homo sapiens* protein tyrosine phosphatase type IVA, member 1 (PTP4A1), mRNA                                                   ref\|NM_003463.3\|      332/335 (99)      3.00×10^−170^   7803 PTP4A1              PTP4A1         6q12
  27    323          *Homo sapiens* chromosome X open reading frame 57 (CXorf57), transcript variant 2, mRNA                                         ref\|NM_001184782.1\|   303/305 (99)      2.00×10^−155^   55086 CXorf57            CXorf57        Xq22.3
  28    214          *Homo sapiens* CREB binding protein (CREBBP), RefSeqGene on chromosome                                                          ref\|NG_009873.1\|        197/198 (99)    1.00×10^−96^    1387                     CREBBP         16p13.3
  29    436          *Homo sapiens* mesencephalic astrocyte-derived neurotrophic factor (MANF), mRNA                                                 ref\|NM_006010.4\|      411/415 (99)      0               7873 MANF                MANF           Unknown
  30    263          *Homo sapiens* ADP-ribosylation factor-like 6 interacting protein 1 (ARL6IP1), mRNA                                             ref\|NM_015161.1\|      243/243 (100)     3.00×10^−124^   23204 ARL6IP1            ARL6IP1        16p12-p11.2
  31    501          *Homo sapiens* RNA, 18S ribosomal 1 (RN18S1), ribosomal RNA                                                                     ref\|NR_003286.2\|      479/480 (99)      0               100008588 RN18S1         RN18S1         Unknown
  32    248          *Homo sapiens* eukaryotic elongation factor-2 kinase (EEF2K), mRNA                                                              ref\|NM_013302.3\|      227/227 (100)     3.00×10^−115^   29904 EEF2K              EEF2K          16p12.1
  33    486          *Homo sapiens* myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, *Drosophila*) (MLL), transcript variant 2, mRNA   ref\|NM_005933.3\|      466/469 (99)      0               4297 MLL                 MLL            11q23
  34    499          PREDICTED: *Macaca mulatta* ATP synthase subunit a-like (LOC100426362), mRNA                                                    ref\|XM_002806045.1\|   359/441 (81)      3.00×10^−93^    100426362 LOC100426362   LOC100426362   Unknown

###### 

Pathway analysis, on the basis of the pathway commons database.

  Signaling pathway                                                Entrez IDs                Enrichment statistics
  ---------------------------------------------------------------- ------------------------- -----------------------------------------------------------
  Notch-HLH transcription                                          1387, 4853                C=6; O=2; E=0.01; R=290.63; rawP=1.93×10^−5^; adjP=0.0004
  TGF-β receptor                                                   1387, 5925, 960           C=126; O=3; E=0.14; R=20.76; rawP=0.0004; adjP=0.0032
  Generic transcription                                            1387, 4853                C=28; O=2; E=0.03; R=62.28; rawP=0.0005; adjP=0.0032
  Microphthalmia-associated transcription factor                   1387, 4286                C=51; O=2; E=0.06; R=34.19; rawP=0.0016; adjP=0.0051
  Signaling events mediated by stem cell factor receptor (c-Kit)   1387, 9611, 4286, 29904   C=436; O=4; E=0.50; R=8.00; rawP=0.0016; adjP=0.0051
  BMP receptor                                                     4086, 4286, 29904         C=189; O=3; E=0.22; R=13.84; rawP=0.0014; adjP=0.0051
  NOTCH                                                            4853, 9611                C=58; O=2; E=0.07; R=30.07; rawP=0.0020; adjP=0.0054
  Regulation of cytoplasmic and nuclear SMAD2/3                    9611, 4286, 29904         C=265; O=3; E=0.30; R=9.87; rawP=0.0035; adjP=0.0066
  TGF-β receptor                                                   9611, 4286, 29904         C=265; O=3; E=0.30; R=9.87; rawP=0.0035; adjP=0.0066
  Androgen receptor                                                1387, 5925                C=79; O=2; E=0.09; R=22.07; rawP=0.0038; adjP=0.0066

###### 

Pathway analysis, on the basis of the Wikipathways database.

  Signaling pathway          Entrez IDs               Enrichment statistics
  -------------------------- ------------------------ ----------------------------------------------------------------
  ∆-Notch                    9611, 4853, 4086, 1956   C=86; O=4; E=0.10; R=40.55; rawP=3.05×10^−6^; adjP=3.97×10^−5^
  Senescence and autophagy   5925, 960, 4297          C=60; O=3; E=0.07; R=43.60; rawP=4.65×10^−5^; adjP=0.0003
  Androgen receptor          1387, 5925, 1956         C=115; O=3; E=0.13; R=22.75; rawP=0.0003; adjP=0.0013
  B cell receptor            5925, 3708, 493          C=158; O=3; E=0.18; R=16.56; rawP=0.0008; adjP=0.0021
  TGF-β receptor             1387, 5925, 960          C=155; O=3; E=0.18; R=16.88; rawP=0.0008; adjP=0.0021
  Notch                      1387, 4853               C=46; O=2; E=0.05; R=37.91; rawP=0.0013; adjP=0.0026
  Id                         5925, 4086               C=51; O=2; E=0.06; R=34.19; rawP=0.0016; adjP=0.0026
  TGF-β                      1387, 4086               C=52; O=2; E=0.06; R=33.53; rawP=0.0016; adjP=0.0026
  Estrogen                   1387, 9611               C=76; O=2; E=0.09; R=22.94; rawP=0.0035; adjP=0.0051
  Wnt and pluripotency       1387, 960                C=98; O=2; E=0.11; R=17.79; rawP=0.0057; adjP=0.0067

[^1]: Contributed equally
